DECISION aims to achieve 4 different goals: (1) To gain a deeper systems level understanding of the pathophysiology leading to cirrhosis, decompensated cirrhosis, and ACLF while respecting individual differences in gender, genetics, and disease history, (2) to provide a proof of concept that novel combinatorial therapies based on systems biology approaches can decrease mortality and significantly improve the lives of patients suffering from cirrhosis, (3) to characterize pathological and therapeutic mechanisms in translational animal models (preclinical research), and (4) to develop robust prognostic and response tests in order to reliably identify patients that are at risk for progression of decompensated cirrhosis following standard treatment but will likely respond well to a novel combinatorial therapy.